Previous studies from this laboratory have shown that pretreatment with phenytoin or phenobarbitone shortens the halflife of MISO in mice and dogs through induction of hepatic drug-metabolizing enzymes, which increase the rate of oxidative demethylation of MISO to desmethylmisonidazole (1-(2-nitroimidazol-1 -yl)-2,3-propandiol; Ro 05-9963, Roche Laboratories; NSC 261036; DEMIS) (Workman, 1979; White & Workman, 1979). In addition, pretreatment with these agents significantly reduces the acute lethal effects of MISO in mice (Workman, 1980 Blood samples were taken by venipuncture immediately before MISO administration and at various times after, usually 2, 1, 2, 4, 8, 12, 24 and 30 h. Plasma concentrations of MISO and DEMIS were determined by reverse-phase high-performance liquid chromatography (HPLC) (Workman et al., 1978a). Pharmacokinetic parameters were calculated as described previously (Workman et al., 1978b; Workman, 1979) . Statistical analysis was by Student's t test.
Previous studies from this laboratory have shown that pretreatment with phenytoin or phenobarbitone shortens the halflife of MISO in mice and dogs through induction of hepatic drug-metabolizing enzymes, which increase the rate of oxidative demethylation of MISO to desmethylmisonidazole (1-(2-nitroimidazol-1 -yl)-2,3-propandiol; Ro 05-9963, Roche Laboratories; NSC 261036; DEMIS) (Workman, 1979; White & Workman, 1979) . In addition, pretreatment with these agents significantly reduces the acute lethal effects of MISO in mice (Workman, 1980 (Workman et al., 1978a) . Pharmacokinetic parameters were calculated as described previously (Workman et al., 1978b; Workman, 1979) . Statistical analysis was by Student's t test.
The pertinent pharmacokinetic data are summarized in Table I . Comparison of the data obtained on the first MISO dose revealed no significant differences between the control and phenytoin groups for any of the kinetic parameters (P> 0 1). This indicated that the pharmacokinetics of MISO were initially very similar for the two groups.
For the control group, comparison of the data for the first and second doses of MISO showed that the percentage change for (Table I) nor the plasma concentration 4 h after administration of the drug (time of irradiation) (Table II) was affected by phenytoin (P > 0. 1). In 4/6 patients the AUC for total plasma 2-nitroimidazole (MISO + DEMIS) was reduced after phenytoin ad- 1st 2nd Dose Dose Dose 9*9+5-3 0.056+0.016 0-052+0 009 6-8+1-3 0-058 + 0-018 0 100 + 0.030 ministration, but this was not significant for the whole group (P > 0 1).
The above data clearly indicate a marked effect of a short course of phenytoin on the pharmacokinetics ofMISO. The shortened half-life and reduced AUC for plasma MISO were associated with a concomitant increase in the concentrations of oxidative metabolite DEMIS. These effects are similar to our recent observations with both phenytoin and phenobarbitone in mice and dogs (Workman, 1979; White & Workman, 1980) .
Phenytoin is known to increase the rate of elimination of many drugs, in experimental animals and in man, by acting as a potent inducer of hepatic microsomal drug-metabolizing enzymes (Conney, 1967; Pirttiaho et al., 1978) . Our data indicate that such induction increases the rate of oxidative demethylation of MISO to DE-MIS. Clinical doses of MISO are limited by its neurotoxicity, particularly peripheral neuropathy, and a total dose not exceeding 12 g/m2 is now recommended (Dische et al., 1977; Urtasun et al., 1978) . Moreover, there is evidence that the incidence of neuropathy is related to the plasma AUC for MISO, and dose adjustment on the basis of plasma pharmacokinetics has been advocated (Saunders et al., 1978) . It therefore appears possible that patients exposed to potent hepatic enzyme-inducing agents, such as phenytoin and phenobarbitone, may be protected to some extent from neurotoxicity by rapid drug clearance. It has not yet been determined, however, whether there is any correlation between phenytoin or phenobarbitone administration and the clinical incidence or severity of MISO neurotoxicity. A study on these lines is in progress.
We should also consider the possible effects of phenytoin on the therapeutic action of MISO. The degree of radiosensitization is a function of tumour MISO concentrationduringirradiation (McNallyetal., 1978) and this is closely related to plasma concentration (Dische et at., 1977; Ash et al., 1979) . Current clinical practice is to irradiate 4 h after MISO administration, and we have shown that neither the peak plasma MISO concentration nor the 4 h concentration is affected by phenytoin. In addition, we have previously shown that peak tumour MISO concentrations are not altered in mice pretreated with phenytoin or phenobarbitone (Workman, 1979) . We therefore feel it is unlikely that phenytoin administration would affect the radiosensitization of tumour cells by MISO. MISO also exhibits selective cytotoxicity towards hypoxic cells (Hall & Roizin-Towle, 1975; Stratford & Adams, 1978) . However, its clinical significance and the effects of enzyme induction on that are unknown.
In conclusion, phenytoin, and possibly other potent liver enzyme-inducing agents such as phenobarbitone, may reduce the incidence of dose-limiting neurotoxicity of MISO without compromising the direct tumour radiosensitization by the drug. The possible effects on the drug's antitumour cytotoxicity are uncertain.
